文献速递脑血管病

血栓通透性增加时血管内治疗获益减弱:7项试验汇总分析

Endovascular Treatment Effect Diminishes With Increasing Thrombus Perviousness: Pooled Data From 7 Trials on Acute Ischemic Stroke.
PubMed 文献 · Stroke · 2021-07-20

该研究基于HERMES汇总数据中443例早期窗口急性缺血性卒中患者,量化血栓通透性并分析其与EVT疗效的交互作用。结果显示通透性越高,对照组(含阿替普酶)功能预后越好,而EVT组无显著关联,提示通透性高的血栓从EVT中额外获益减弱。

要点

  • 血栓通透性越高,对照组(最佳药物治疗含阿替普酶)90天功能预后越好。
  • EVT组中通透性与功能预后无显著关联,提示EVT额外获益随通透性增加而减弱。
  • 通透性增高与随访梗死体积减小和死亡率降低相关,无显著治疗交互作用。

核心结论

  • 与额外EVT相比,包含阿替普酶的最佳药物治疗在血栓通透性更高的患者中获益增加。

研究设计与样本

  • 汇总HERMES数据集7项EVT随机试验,纳入443例有薄层影像的早期窗口患者(多数在8小时内)。
  • 对照组233例,符合条件者接受静脉阿替普酶(212/233;91%);干预组210例接受额外EVT(178/210既往阿替普酶;85%)。
  • 通透性通过入院CTA与平扫CT的血栓衰减增加值量化,采用多变量回归分析含交互项。

主要发现

  • 通透性增加与功能预后改善相关;加入通透性与治疗分配的交互项后模型拟合显著改善(P=0.03)。
  • 对照组通透性增加与更好预后显著相关(调整共同OR 1.2 [95%CI 1.1–1.3])。
  • EVT组通透性与预后无显著关联(调整共同OR 1.0 [95%CI 0.9–1.1]),且与成功再灌注无显著相关。
  • 总体人群中,每5个Hounsfield单位血栓衰减增加,随访梗死体积减少12%(95%CI 7.0–17),死亡几率降低(调整OR 0.83 [95%CI 0.70–0.97]),无显著治疗交互。

关键数值与推荐

  • 主要结局为90天功能结局(改良Rankin量表评分),报告为一步改善的调整共同OR。
  • 次要结局包括死亡率、成功再灌注(eTICI 2B–3)和随访梗死体积(mL)。

临床怎么用

  • 血栓通透性高的急性缺血性卒中患者,最佳药物治疗(含阿替普酶)的获益可能增加,EVT额外获益减弱。
  • 通透性可作为EVT获益的潜在修饰因子,辅助个体化治疗决策。

局限性

  • 仅纳入有薄层影像的443例患者,可能存在选择偏倚。
  • 为汇总数据的事后分析,交互作用需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Thrombus perviousness estimates residual flow along a thrombus in acute ischemic stroke, based on radiological images, and may influence the benefit of endovascular treatment for acute ischemic stroke. We aimed to investigate potential endovascular treatment (EVT) effect modification by thrombus perviousness. METHODS: We included 443 patients with thin-slice imaging available, out of 1766 patients from the pooled HERMES (Highly Effective Reperfusion Evaluated in Multiple Endovascular Stroke trials) data set of 7 randomized trials on EVT in the early window (most within 8 hours). Control arm patients (n=233) received intravenous alteplase if eligible (212/233; 91%). Intervention arm patients (n=210) received additional EVT (prior alteplase in 178/210; 85%). Perviousness was quantified by thrombus attenuation increase on admission computed tomography angiography compared with noncontrast computed tomography. Multivariable regression analyses were performed including multiplicative interaction terms between thrombus attenuation increase and treatment allocation. In case of significant interaction, subgroup analyses by treatment arm were performed. Our primary outcome was 90-day functional outcome (modified Rankin Scale score), resulting in an adjusted common odds ratio for a one-step shift towards improved outcome. Secondary outcomes were mortality, successful reperfusion (extended Thrombolysis in Cerebral Infarction score, 2B–3), and follow-up infarct volume (in mL). RESULTS: Increased perviousness was associated with improved functional outcome. After adding a multiplicative term of thrombus attenuation increase and treatment allocation, model fit improved significantly (P=0.03), indicating interaction between perviousness and EVT benefit. Control arm patients showed significantly better outcomes with increased perviousness (adjusted common odds ratio, 1.2 [95% CI, 1.1–1.3]). In the EVT arm, no significant association was found (adjusted common odds ratio, 1.0 [95% CI, 0.9–1.1]), and perviousness was not significantly associated with successful reperfusion. Follow-up infarct volume (12% [95% CI, 7.0–17] per 5 Hounsfield units) and chance of mortality (adjusted odds ratio, 0.83 [95% CI, 0.70–0.97]) decreased with higher thrombus attenuation increase in the overall population, without significant treatment interaction. CONCLUSIONS: Our study suggests that the benefit of best medical care including alteplase, compared with additional EVT, increases in patients with more pervious thrombi.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Kappelhof M, Tolhuisen ML, Treurniet KM, et al. Endovascular Treatment Effect Diminishes With Increasing Thrombus Perviousness: Pooled Data From 7 Trials on Acute Ischemic Stroke. Stroke. 2021. PMID: 34281377. doi:10.1161/STROKEAHA.120.033124

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。